The Undisclosed Ozempic Effect: Shrinking More Than Just Your Waistline
GLP-1 drugs are changing the treatment of obesity. The question of what else changes alongside weight has only recently begun to receive sustained attention.
The clinical impact of semaglutide has been notable by any standard. In the STEP 1 trial, weekly doses of 2.4 mg produced average weight reductions of approximately 15% over 68 weeks—outcomes that exceed what lifestyle interventions alone tend to achieve. Tirzepatide, which targets both GLP-1 and GIP receptors, has demonstratedeven greater reductions, approaching 20% in some studies. These results are not in dispute. What is less frequently examined is the composition of that weight loss. Body weight is not a uniform entity, and reductions in total mass do not distinguish between fat and other tissues.
💡 There's more to what Ozempic marketing suggests. [Read the full breakdown of the science below ↓]
Recent analyses suggest that this distinction matters. A 2024 systematic review and network meta-analysis, encompassing more than 2,000 participants across multiple randomized trials, reported that GLP-1 receptor agonists reduce both fat mass and lean mass. On average, lean tissue accounted for roughly one quarter of totalweight lost. In practical terms, this implies that for every four kilograms of weight reduction, approximately one kilogram may come from non-fat tissue. Findings from the STEP 1 trial itself indicate that reductions in lean mass can be substantial, though estimates vary depending on measurement methods and study conditions. Lean mass, importantly, is not synonymous with muscle alone. It includes connective tissue, bone, organs, and structural proteins that contribute to the body’s physical integrity. The long-term implications of reducing these components at scale are still being clarified.
Collagen is central to this discussion. It represents a significant proportion of the body’s protein content and provides structural support to skin, cartilage, tendons, and bone. Its synthesis depends on the availability of specific amino acids—primarily glycine, proline, and hydroxyproline—as well as sufficient energy intake to sustain cellular processes. GLP-1 receptor agonists exert much of their effect by suppressing appetite and slowing gastric emptying, which often leads to a sustained caloric deficit. Under these conditions, the substrates required for ongoing tissue maintenance may become limited. One observable consequence, reported anecdotally and increasingly discussed in clinical settings, is a change in skin quality during rapid weight loss. While often framed in cosmetic terms, such changes reflect broader shifts in connective tissue dynamics.
The evidence, however, is not uniform. Some longitudinal and cohort studies suggest that initial declines in lean mass may stabilize over time, particularly when functional measures such as strength are considered. There are also documented cases in which individuals preserved—or in some instances increased—lean tissue while undergoing GLP-1 therapy. These outcomes were typically associated with consistent resistance training and adequate protein intake. The pattern is clear: loss of lean mass is not an unavoidable consequence, but it is a likely one in the absence of deliberate intervention.
Want more science-backed wellness insights? Follow us on Instagram and Facebook and subscribe to our newsletter and be the first to get our deep dives.
